查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018825

血管閉合器械市場：2026-2032年全球市場預測（依產品類型、手術類型、入路部位、最終用戶及通路分類）

Vascular Closure Device Market by Product Type, Procedure Type, Access Site, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血管閉合裝置市場價值將達到 18.5 億美元，到 2026 年將成長到 20 億美元，到 2032 年將達到 31.1 億美元，複合年成長率為 7.71%。

主要市場統計數據
基準年 2025 18.5億美元
預計年份：2026年 20億美元
預測年份 2032 31.1億美元
複合年成長率 (%) 7.71%

權威的介紹概述了重塑血管閉合裝置選擇的臨床重點、監管壓力和程序趨勢。

血管閉塞器械市場處於臨床需求、手術效率和器械創新三者交會點。過去十年，臨床醫生和醫院管理者一直優先考慮能夠縮短止血時間、降低併發症率並提高患者處理速度，同時又不影響手術安全性的解決方案。因此，技術開發商推出了一系列機械和生物學方法，旨在應對不同入路部位的挑戰，並能融入各種不同的手術流程。

臨床實踐、設備創新和採購趨勢的關鍵變革正在重新定義血管閉塞設備的現狀。

血管閉塞裝置市場正經歷多項變革，其驅動力包括不斷發展的臨床實踐、技術的進步以及醫療服務體系的重組。首先，臨床上迫切需要能夠促進早期活動並減少穿刺部位併發症的裝置，這反過來又提高了對裝置安全性和易用性的要求。臨床醫生越來越傾向於選擇能夠最大限度減少手動壓迫時間且符合當日出院流程的解決方案，尤其是在門診和日間護理機構中。

2025 年美國關稅措施將如何重塑整個醫療設備價值鏈的供應鏈策略、產品優先順序和定價趨勢？

美國2025年實施的關稅措施對整個供應鏈產生了重大影響，波及醫療設備製造商的零件採購、生產策略和定價趨勢。對某些進口材料和子組件徵收的關稅迫使企業重新評估供應商所在地，加快關鍵零件的近岸外包，並在某些情況下重新設計供應鏈以減輕額外關稅的影響。這些營運應對措施在那些先前依賴單一來源進口精密聚合物、生物來源原料或專有輸送組件的企業中尤為顯著。

細分市場的洞察揭示了產品設計、治療環境、接入點特徵、最終用戶需求和通路如何影響部署模式。

對市場細分的詳細分析揭示了臨床需求與產品特性和銷售管道之間的相互作用。根據產品類型，該領域包括夾式裝置、膠原蛋白塞裝置、外部壓迫裝置、密封劑型裝置和縫合式裝置。在膠原蛋白塞裝置中，牛膠原蛋白塞和合成膠原膠原蛋白塞之間的差異會影響臨床醫生的選擇，因為他們會考慮生物相容性和吸收特性。同時，密封劑的選擇，例如幾丁聚醣基密封劑和聚乙二醇基密封劑，則體現了黏合強度和促炎特性之間的權衡。這些產品層面的差異不僅影響臨床選擇，也影響培訓需求和庫存計畫。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略意義將指南針對每個地區量身定做的市場策略。

區域趨勢對臨床偏好、監管方式和商業策略有顯著影響。在美洲，臨床實踐趨勢的特徵是橈動脈和股動脈入路方式的廣泛應用、日益注重效率的漸進式報銷模式，以及集中分佈的大規模綜合醫療保健系統。這些系統在可靠的實證醫學證據支持下，能夠加速創新技術的推廣應用。供應鏈的接近性和國內製造能力也會影響採購決策，進而影響企業在區域內建立分銷和服務模式的方式。

競爭格局分析和企業策略：這揭示了成熟公司、新興企業和合作夥伴如何塑造其設備組合和夥伴關係關係的未來。

血管閉塞器材領域的競爭動態呈現出兩難平衡：一方面是憑藉臨床經驗佔優勢的老牌企業，另一方面是依靠創新和成本效益展開競爭的新興參與企業。老牌企業通常受益於與大規模醫院系統的緊密合作關係、完善的培訓項目以及廣泛的上市後監測數據，這些數據有助於其不斷改進產品。同時，新興企業則經常透過引入差異化材料、簡化的植入機製或提供能夠證明特定手術優勢的臨床證據，來抓住市場機會。

為製造商和相關人員提供可操作且優先考慮的建議，以加快採用速度、加強供應鏈，並使證據與醫療保健提供者的優先事項保持一致。

產業領導者應採取協作方式，將產品創新、臨床證據產生和供應鏈韌性結合，以掌握介入醫學領域的新機會。首先，應優先改善設計，降低手術複雜性，並提高實施的一致性，使其不受操作者技能水準的影響。更易於使用和直覺的作業系統能夠降低訓練門檻，並加速在門診和住院環境中的應用。其次，應投資於臨床證據項目，將設備性能與醫療服務提供者重視的運作結果（例如止血時間、恢復活動時間以及減少術後併發症）明確聯繫起來。

高度透明的調查方法，結合對臨床醫生的訪談、證據整合和資料檢驗，確保了可靠且可操作的見解。

本概要的研究結合了對臨床醫生、採購經理和行業高管的訪談，以及對監管申報文件、同行評審的臨床文獻和真實世界數據（REW）來源的嚴謹的二手資料研究。主要研究包括結構化訪談和深入的定性對話，旨在識別臨床醫生的工作流程限制、培訓需求以及影響採購決策的因素。此外，還與醫療系統管理人員進行了諮詢，以明確營運重點和資源分配方面的考慮。

將臨床需求、技術創新和策略行動連結起來，實現永續應用和改善結果，從而形成簡潔、全面的整合方案。

總之，血管閉塞裝置領域正面臨雙重壓力：一方面是臨床對更安全、更快速止血的需求，另一方面是商業性對實際價值的需求。科技創新為滿足以往未被滿足的需求開闢了新的機遇，同時，醫療流程和醫療服務模式的變革也正在重新定義這些裝置的使用範圍和方式。能夠成功地將產品設計與臨床醫生的工作流程、監管要求和穩健的供應鏈相結合的機構，將更有能力將創新轉化為永續的應用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血管閉合裝置市場：依產品類型分類

  • 夾式裝置
  • 膠原蛋白塞裝置
    • 牛膠原蛋白塞
    • 合成膠原膠原蛋白塞
  • 外部壓縮裝置
  • 密封裝置
    • 幾丁聚醣基密封劑
    • 聚乙二醇基密封劑
  • 基於縫合線的裝置

第9章 血管閉合裝置市場（依治療類型分類）

  • 診斷治療
    • 血管造影術
    • 血流動力學監測
  • 介入治療
    • 介入心臟病學
    • 周邊血管介入治療

第10章：市場進入

  • 股動脈路徑
  • 徑向通道

第11章 血管閉合裝置市場：依最終用戶分類

  • 門診手術中心
  • 診所
  • 醫院

第12章 血管閉合器械市場：依分銷管道分類

  • 直銷
  • 第三方經銷商

第13章 血管閉合器械市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血管閉合器械市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血管閉合器械市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血管閉合裝置市場

第17章：中國血管閉合器材市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Advanced Vascular Dynamics, LLC
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Cook Medical LLC
  • Essential Medical, Inc.
  • Forge Medical AB
  • Haemonetics Corporation
  • InSeal Medical Ltd.
  • Lake Region Medical, Inc.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • Merit Medical Systems, Inc.
  • Morris Innovative, Inc.
  • Rex Medical, LP
  • Teleflex Incorporated
  • Terumo Corporation
  • Tricol Biomedical, Inc.
  • TZ Medical, Inc.
  • Vasorum Ltd.
  • Vivasure Medical Ltd.
Product Code: MRR-ED54C46E8A80

The Vascular Closure Device Market was valued at USD 1.85 billion in 2025 and is projected to grow to USD 2.00 billion in 2026, with a CAGR of 7.71%, reaching USD 3.11 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.85 billion
Estimated Year [2026] USD 2.00 billion
Forecast Year [2032] USD 3.11 billion
CAGR (%) 7.71%

An authoritative introduction framing clinical priorities, regulatory pressures, and procedural trends that are reshaping vascular closure device choices

The vascular closure device landscape sits at the intersection of clinical need, procedural efficiency, and device innovation. Over the past decade, clinicians and hospital administrators have prioritized solutions that reduce time to hemostasis, lower complication rates, and enable faster patient throughput without compromising procedural safety. Consequently, technology developers have responded with a range of mechanical and biological approaches designed to address distinct access-site challenges while integrating with diverse procedural workflows.

Regulatory pathways, reimbursement pressures, and an increasingly outcomes-driven purchasing environment continue to shape device development and adoption. As institutions seek demonstrable reductions in length of stay and post-procedural complications, clinical evidence and real-world performance data have become decisive factors in procurement decisions. At the same time, procedural trends such as the expansion of radial access and the shift of lower-risk interventions to ambulatory settings are redefining clinical requirements and use cases.

Taken together, these forces create a dynamic environment where incremental improvements in ease of use, safety profile, and compatibility with minimally invasive approaches can yield significant clinical and operational advantages. This introduction establishes the core themes explored throughout the rest of this summary: technological differentiation, procedural alignment, regulatory considerations, and the changing needs of providers and payers.

Key transformative shifts in clinical practice, device innovation, and procurement dynamics that are redefining the vascular closure device landscape

The landscape for vascular closure devices is undergoing several transformative shifts driven by clinical practice evolution, technological refinement, and care-delivery reorganization. First, there is a clear clinical push toward devices that facilitate earlier ambulation and reduce access-site complications, which in turn raises the bar for demonstrable safety and ease of deployment. Clinicians increasingly favor solutions that minimize manual compression time and are compatible with same-day discharge pathways, especially in outpatient or ambulatory settings.

Second, device innovation is migrating from purely mechanical solutions to hybrid and biologically active approaches that aim to accelerate hemostasis while reducing foreign-body reactions. This trend includes refinement of suture-based closure techniques, development of resorbable plugs with optimized biointegration, and sealants formulated to adhere effectively under challenging hemodynamic conditions. Meanwhile, manufacturers are focusing on usability enhancements-ergonomic delivery systems, simplified training workflows, and clear procedural guidance-to reduce variability in clinical outcomes.

Third, the structural dynamics of healthcare procurement are altering market access strategies. Hospital systems and ambulatory surgical centers are consolidating purchasing frameworks and demanding robust real-world evidence and post-market surveillance data. These shifts require manufacturers to develop comprehensive value dossiers that link clinical performance to operational benefits and resource utilization. As a result, strategic collaborations between device companies, clinical leaders, and health systems are becoming an essential pathway to adoption.

How the 2025 United States tariff measures reshaped supply chain strategies, product prioritization, and pricing dynamics across the device value chain

The introduction of United States tariff measures in 2025 has exerted a notable influence across the supply chain, affecting component sourcing, manufacturing strategies, and pricing dynamics for device manufacturers. Tariffs on certain imported materials and subassemblies have prompted companies to reassess supplier footprints, accelerate nearshoring of critical components, and in some cases, redesign supply chains to mitigate exposure to incremental duties. These operational responses have been particularly pronounced for firms that previously relied on single-source imports for precision polymers, biologic feedstocks, or proprietary delivery components.

In parallel, tariff-driven cost pressures have led several manufacturers to re-evaluate product portfolios and prioritize investments in higher-margin, differentiated technologies over commoditized offerings. This shift has implications for competitive positioning, as smaller players with less flexible supply chains face heightened margin compression while larger organizations leverage scale to absorb or offset duty increases. Additionally, procurement teams at health systems are responding to downstream pricing adjustments by conducting more rigorous cost-benefit analyses, emphasizing total cost of care and supplier reliability over unit price alone.

Finally, regulatory and trade uncertainty has prompted a renewed focus on inventory resilience and contractual safeguards. Companies are increasingly negotiating longer-term agreements with suppliers, diversifying vendor bases, and investing in supply chain visibility tools to anticipate and respond to tariff-related disruptions. As a result, the 2025 tariff environment has catalyzed strategic realignment across manufacturing, procurement, and commercial operations.

Segment-driven insights revealing how product design, procedural context, access site dynamics, end-user requirements, and distribution paths shape adoption patterns

A nuanced examination of segmentation reveals where clinical needs intersect with product capabilities and commercial channels. Based on product type, the field includes Clip Based Devices, Collagen Plug Devices, External Compression Devices, Sealant Based Devices, and Suture Based Devices; within collagen plugs, distinctions between Bovine Collagen Plugs and Synthetic Collagen Plugs influence clinician preference based on biocompatibility concerns and resorption profiles, while sealant choices such as Chitosan Sealants and Polyethylene Glycol Sealants reflect trade-offs between adhesive strength and inflammatory potential. These product-level differences affect not only clinical selection but also training requirements and inventory planning.

Turning to procedure type, diagnostic procedures encompass Angiographic Procedures and Hemodynamic Monitoring where rapid hemostasis and minimal interference with vascular imaging are paramount, whereas interventional procedures include Cardiovascular Interventions and Peripheral Vascular Interventions that demand closure reliability under higher anticoagulation or larger-bore sheath scenarios. Access site segmentation-Femoral Access versus Radial Access-continues to be a critical determinant of device relevance, with radial access driving demand for lower-profile, user-friendly systems and femoral access sustaining the need for robust mechanical closure options.

End user distinctions among Ambulatory Surgical Centers, Clinics, and Hospitals shape purchasing behavior and device adoption timelines, as ambulatory settings prioritize throughput and ease of use while hospitals emphasize comprehensive clinical evidence and multi-operator applicability. Distribution channel dynamics split between Direct Sales and Third Party Distributors, with direct sales enabling closer clinical training and value proposition alignment and third party distributors offering breadth and reach across heterogeneous customer bases. Together, these segmentation layers create multiple pathways for targeted product development and differentiated go-to-market strategies.

Regional dynamics and strategic implications across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform tailored market approaches

Regional dynamics exert a strong influence on clinical preferences, regulatory approaches, and commercial strategies. In the Americas, clinical practice patterns are characterized by broad adoption of both radial and femoral access techniques, progressive reimbursement models that increasingly reward efficiency, and a concentrated group of large integrated health systems that can accelerate adoption of innovations when supported by robust evidence. Supply chain proximity and domestic manufacturing capabilities also play a role in procurement decisions, influencing how companies structure distribution and service models within the region.

In Europe, Middle East & Africa, heterogeneous regulatory environments and a diversity of healthcare delivery settings create both challenges and opportunities for market entrants. Reimbursement mechanisms vary widely across countries, and local clinical guidelines often influence device selection more than multinational promotional efforts. Meanwhile, several EMEA markets show a growing appetite for minimally invasive approaches and outpatient interventions, which in turn drives demand for devices that prioritize ease of use and predictable outcomes.

Across Asia-Pacific, the combination of rapid procedural growth, expanding interventional capabilities, and varied payer landscapes creates a complex but high-potential environment. Countries within the region differ in their regulatory timelines and local manufacturing ecosystems, prompting manufacturers to pursue flexible commercial models that accommodate both centralized hospital networks and rapidly expanding ambulatory providers. Overall, regional strategies must be tailored to align clinical adoption drivers with regulatory realities and supply chain considerations.

Competitive landscape analysis and corporate strategies highlighting how incumbents, challengers, and collaborators are shaping the future of device portfolios and partnerships

Competitive dynamics in the vascular closure device arena are characterized by a balance between established players that leverage clinical legacy and newer entrants that compete on innovation and cost-efficiency. Incumbent firms often benefit from deep relationships with large hospital systems, comprehensive training programs, and extensive post-market surveillance data that inform iterative product improvements. Conversely, challenger companies frequently exploit niche opportunities by introducing differentiated materials, simplified deployment mechanisms, or focused clinical evidence demonstrating specific procedural advantages.

Partnerships and strategic alliances are increasingly common, as device makers collaborate with contract manufacturers, academic centers, and health systems to accelerate clinical validation and scale manufacturing. Capital allocation patterns reveal a preference for funding technologies that reduce procedural time or demonstrably lower complication risks, because these outcomes align closely with health system quality metrics and reimbursement priorities. Additionally, a trend toward consolidation and selective acquisition remains visible, as larger organizations seek to broaden product portfolios and secure access to innovative technologies without internal development lag.

For manufacturers, maintaining a balance between regulatory compliance, supply chain resilience, and continuous clinical engagement is essential. Companies that invest in robust clinician education, transparent performance measurement, and adaptable supply arrangements are better positioned to navigate shifting procurement criteria and to capture opportunities presented by changes in procedural practice and care delivery models.

Practical, prioritized recommendations for manufacturers and stakeholders to accelerate adoption, strengthen supply chains, and align evidence with provider priorities

Industry leaders should pursue a coordinated approach that combines product innovation, clinical evidence generation, and supply chain resilience to capture emerging opportunities in procedural care. First, prioritize design enhancements that reduce procedural complexity and improve deployment consistency across operator skill levels; usability improvements and intuitive delivery systems lower training barriers and accelerate uptake in ambulatory and hospital settings. Second, invest in clinical evidence programs that clearly align device performance with operational outcomes valued by providers, such as time to hemostasis, return-to-activity timelines, and reduced post-procedural complications.

Simultaneously, strengthen supply chain strategies by diversifying supplier bases, assessing nearshoring options for critical components, and negotiating contractual terms that provide flexibility under tariff and trade uncertainties. Commercially, tailor go-to-market models to end-user needs by offering differentiated value propositions: provide training and service bundles for hospital systems, emphasize throughput and ease-of-use benefits for ambulatory surgical centers, and leverage distributor networks for broad geographic reach where direct sales are impractical. Finally, cultivate partnerships with clinical leaders and health system purchasers to co-develop evidence, deploy pilot programs, and secure long-term adoption commitments that demonstrate shared accountability for outcomes.

Taken together, these actions will improve competitiveness, reduce exposure to operational shocks, and increase the likelihood that device innovations translate into sustained clinical and commercial impact.

Transparent research methodology combining clinician interviews, evidence synthesis, and data triangulation to ensure credible, actionable insights

The research underpinning this summary combined primary interviews with clinicians, procurement leaders, and industry executives alongside rigorous secondary review of regulatory filings, peer-reviewed clinical literature, and real-world evidence sources. Primary research consisted of structured interviews and qualitative depth conversations designed to surface clinician workflow constraints, training needs, and procurement decision drivers. These engagements were complemented by advisory consultations with health system administrators to contextualize operational priorities and resource allocation considerations.

Secondary research included systematic review of clinical studies, procedure guidelines, and regulatory documentation to validate claims of device safety and performance. Data triangulation techniques were applied to reconcile insights from interviews with published outcomes and device labeling information, ensuring that recommendations reflect convergent evidence rather than isolated anecdotes. Care was taken to anonymize proprietary information and to synthesize learnings into generalized themes applicable across different organizational contexts.

Quality assurance processes included cross-checks by clinical subject-matter experts, verification of cited regulatory references, and iterative review cycles to refine conclusions. The methodology emphasizes transparency, repeatability, and alignment with industry best practices to provide stakeholders with a credible basis for strategic planning and operational decision-making.

Concise concluding synthesis connecting clinical needs, technological innovation, and strategic actions to achieve durable adoption and improved outcomes

In conclusion, the vascular closure device domain is evolving under the twin pressures of clinical demand for safer, faster hemostasis and commercial imperatives that reward demonstrable value. Technological innovation is unlocking opportunities to address previously unmet needs, while procedural trends and care-delivery shifts are redefining where and how these devices are used. Organizations that successfully align product design with clinician workflows, regulatory expectations, and resilient supply chains will be best positioned to translate innovation into durable adoption.

Moreover, the shifting commercial environment-accentuated by trade policy changes, procurement consolidation, and regional variability-requires flexible strategies that combine robust clinical evidence with adaptive distribution and manufacturing approaches. By focusing on targeted segmentation, rigorous outcome measurement, and collaborative pilots with health systems, stakeholders can accelerate meaningful adoption while managing operational risk. Ultimately, a disciplined, evidence-led approach will be essential for converting technological potential into improved patient outcomes and sustainable commercial performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vascular Closure Device Market, by Product Type

  • 8.1. Clip Based Devices
  • 8.2. Collagen Plug Devices
    • 8.2.1. Bovine Collagen Plugs
    • 8.2.2. Synthetic Collagen Plugs
  • 8.3. External Compression Devices
  • 8.4. Sealant Based Devices
    • 8.4.1. Chitosan Sealants
    • 8.4.2. Polyethylene Glycol Sealants
  • 8.5. Suture Based Devices

9. Vascular Closure Device Market, by Procedure Type

  • 9.1. Diagnostic Procedures
    • 9.1.1. Angiographic Procedures
    • 9.1.2. Hemodynamic Monitoring
  • 9.2. Interventional Procedures
    • 9.2.1. Cardiovascular Interventions
    • 9.2.2. Peripheral Vascular Interventions

10. Vascular Closure Device Market, by Access Site

  • 10.1. Femoral Access
  • 10.2. Radial Access

11. Vascular Closure Device Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Hospitals

12. Vascular Closure Device Market, by Distribution Channel

  • 12.1. Direct Sales
  • 12.2. Third Party Distributors

13. Vascular Closure Device Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Vascular Closure Device Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Vascular Closure Device Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Vascular Closure Device Market

17. China Vascular Closure Device Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Advanced Vascular Dynamics, LLC
  • 18.7. B. Braun Melsungen AG
  • 18.8. Becton, Dickinson and Company
  • 18.9. BIOTRONIK SE & Co. KG
  • 18.10. Boston Scientific Corporation
  • 18.11. Cardinal Health, Inc.
  • 18.12. Cook Medical LLC
  • 18.13. Essential Medical, Inc.
  • 18.14. Forge Medical AB
  • 18.15. Haemonetics Corporation
  • 18.16. InSeal Medical Ltd.
  • 18.17. Lake Region Medical, Inc.
  • 18.18. Medtronic plc
  • 18.19. Meril Life Sciences Pvt. Ltd.
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. Morris Innovative, Inc.
  • 18.22. Rex Medical, L.P.
  • 18.23. Teleflex Incorporated
  • 18.24. Terumo Corporation
  • 18.25. Tricol Biomedical, Inc.
  • 18.26. TZ Medical, Inc.
  • 18.27. Vasorum Ltd.
  • 18.28. Vivasure Medical Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VASCULAR CLOSURE DEVICE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VASCULAR CLOSURE DEVICE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLIP BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLIP BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLIP BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY BOVINE COLLAGEN PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY BOVINE COLLAGEN PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY BOVINE COLLAGEN PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SYNTHETIC COLLAGEN PLUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SYNTHETIC COLLAGEN PLUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SYNTHETIC COLLAGEN PLUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY EXTERNAL COMPRESSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY EXTERNAL COMPRESSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY EXTERNAL COMPRESSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CHITOSAN SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CHITOSAN SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CHITOSAN SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY POLYETHYLENE GLYCOL SEALANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY POLYETHYLENE GLYCOL SEALANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY POLYETHYLENE GLYCOL SEALANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SUTURE BASED DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SUTURE BASED DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY SUTURE BASED DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY ANGIOGRAPHIC PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY ANGIOGRAPHIC PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY ANGIOGRAPHIC PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HEMODYNAMIC MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HEMODYNAMIC MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HEMODYNAMIC MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CARDIOVASCULAR INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CARDIOVASCULAR INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CARDIOVASCULAR INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR INTERVENTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR INTERVENTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY PERIPHERAL VASCULAR INTERVENTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY FEMORAL ACCESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY FEMORAL ACCESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY FEMORAL ACCESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY RADIAL ACCESS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY RADIAL ACCESS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY RADIAL ACCESS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 173. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 175. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 176. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 177. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 202. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 203. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 205. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 206. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 207. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 212. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 213. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 215. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 216. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 217. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL VASCULAR CLOSURE DEVICE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 226. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 227. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 228. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY COLLAGEN PLUG DEVICES, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY SEALANT BASED DEVICES, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DIAGNOSTIC PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY INTERVENTIONAL PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY ACCESS SITE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA VASCULAR CLOSURE DEVICE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)